Monitoring of KRAS-mutated ctDNA to discriminate pseudoprogression from true progression during anti-PD-1 treatment of lung adenocarcinoma

Oncotarget

Volumn 8, Issue 23, 2017, Pages 38056-38060

  Guibert, Nicolas ^a,b,d   Mazieres, Julien ^a,b,d   Delaunay, Myriam ^a,b,d   Casanova, Anne ^b,c   Farella, Magali ^b,c   Keller, Laura ^b,c   Favre, Gilles ^b,c,d   Pradines, Anne ^b,c  

^a SERVICE DE PNEUMOLOGIE   (France)

^b CANCER RESEARCH CENTER OF TOULOUSE   (France)

^c INSTITUT CLAUDIUS REGAUD   (France)

^d UNIVERSITÉ PAUL SABATIER   (France)

Author keywords

Anti PD 1; Circulating tumor DNA; Immunotherapy; KRAS mutation; Non small cell lung cancer

Indexed keywords

CHLOROPLAST DNA; GENOMIC DNA; NIVOLUMAB; PROGRAMMED DEATH 1 LIGAND 1; ATEZOLIZUMAB; CIRCULATING TUMOR DNA; MONOCLONAL ANTIBODY;

ARTICLE; BLOOD SAMPLING; CANCER CELL LINE; CANCER GROWTH; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DROPLET DIGITAL POLYMERASE CHAIN REACTION; DRUG RESPONSE; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG ADENOCARCINOMA; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; ONCOGENE K RAS; OUTCOME ASSESSMENT; PSEUDOPROGRESSION; ADENOCARCINOMA; DISEASE EXACERBATION; GENETICS; IMMUNOTHERAPY; LUNG TUMOR; NON SMALL CELL LUNG CANCER; PATHOLOGY; PROCEDURES;

ADENOCARCINOMA; ADENOCARCINOMA OF LUNG; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CARCINOMA, NON-SMALL-CELL LUNG; CIRCULATING TUMOR DNA; DISEASE PROGRESSION; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS;

EID: 85020162346     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.16935     Document Type: Article

References (11)

1. Guibert N, Mazières J. Nivolumab for treating non-small cell lung cancer. Expert Opin Biol Ther. 2015; 15:1789-97
2. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS. Guidelines for the evaluation of immune therapy activity in solid tumors: Immune-related response criteria. Clin Cancer Res. 2009; 15:7412-7420
3. Hodi FS, Sznol M, Kluger HM, McDermott DF, Carvajal RD, Lawrence DP, Topalian SL, Atkins MB, Powderly JD, Sharfman WH, Puzanov I, Smith DC, Leming PD, et al. Long term survival of ipilimumab-naive patients with advanced melanoma treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trial. J Clin Oncol. 2014; 15: abstr 9002
4. Hodi SF, Ribas A, Daud A, Hamid O, Robert C, Kefford R, Hwu WJ, Gangadhar TC, Joshua AM, Hersey P, Weber JS, Dronca RS, Perrone AM, et al. Evaluation of immunerelated response criteria (irRC) in patients (pts) with advanced melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475. J Clin Oncol. 2014; 15: abstr 3006
5. Guibert N, Pradines A, Farella M, Casanova A, Gouin S, Keller L, Favre G, Mazieres J. Monitoring KRAS mutations in circulating DNA and tumor cells using digital droplet PCR during treatment of KRAS-mutated lung adenocarcinoma. Lung Cancer. 2016; 100:1-4
6. Spigel DR, Schrock AB, Fabrizio D, Frampton GM, Sun J, He J, Gowen K, Johnson ML, Bauer TM, Kalemkerian GP, Raez LE, Ou SI, Ross JS, et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. J Clin Oncol. 2016; 34: abstract 9017
7. Li D, Zhu X, Li N, Li Y. Correlation of PD-L1 expression with EGFR, KRAS, or ALK alterations and with survival of non-small cell lung cancer (NSCLC) treated with EGFRTKIs: a meta-analysis of published trials. J Clin Oncol. 2016; 34: abstract e20576
8. Sacher AG, Paweletz C, Dahlberg SE, Alden RS, O'Connell A, Feeney N, Mach SL, Jänne PA, Oxnard GR. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer. JAMA Oncol. 2016; 2:1014-22
9. Rainer TH, Lam NYL. Circulating nucleic acids and critical illness. Ann NY Acad Sci. 2006; 1075:271-277
10. Guibert N, Pradines A, Casanova A, Farella M, Keller L, Soria JC, Favre G, Mazières J. Detection and monitoring of the BRAF mutation in circulating tumor cells and circulating tumor DNA in BRAF-mutated lung adenocarcinoma. J Thorac Oncol. 2016; 11:e109-12
11. Oxnard GR, Paweletz CP, Kuang Y, Mach SL, O'Connell A, Messineo MM, Luke JJ, Butaney M, Kirschmeier P, Jackman DM, Jänne PA. Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res. 2014; 20:1698-1705